Race Oncology (ASX:RAC) filed an application with the Bellberry Human Research Ethics Committee for a phase 1 trial investigating the use of the RC220 bisantrene in combination with doxorubicin to potentially treat solid tumors, according to a Thursday filing made with the Australian bourse.
Once approved, the biopharmaceutical firm will activate the first trial site in New South Wales, with an additional 10 sites to follow, the filing said.
Patient recruitment for the trial is scheduled for the first quarter of next year, the filing added.
The company's shares surged past 9% in recent Thursday trade.
Price (AUD): $1.41, Change: $+0.12, Percent Change: +9.33%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。